Mayfair Advisory Group LLC Takes $203,000 Position in Danaher Co. (NYSE:DHR)

Mayfair Advisory Group LLC purchased a new stake in shares of Danaher Co. (NYSE:DHR) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 751 shares of the conglomerate’s stock, valued at approximately $203,000.

Other institutional investors have also recently made changes to their positions in the company. CarsonAllaria Wealth Management Ltd. bought a new stake in Danaher in the 2nd quarter worth approximately $25,000. nVerses Capital LLC bought a new stake in Danaher in the 2nd quarter worth approximately $25,000. Redmont Wealth Advisors LLC bought a new stake in Danaher in the 1st quarter worth approximately $30,000. MFA Wealth Advisors LLC bought a new stake in Danaher in the 2nd quarter worth approximately $51,000. Finally, Financial Connections Group Inc. bought a new stake in Danaher in the 2nd quarter worth approximately $51,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Wall Street Analyst Weigh In

DHR has been the subject of a number of research analyst reports. TD Cowen lifted their target price on shares of Danaher from $310.00 to $315.00 and gave the stock a “buy” rating in a research report on Wednesday. Leerink Partners lifted their price target on shares of Danaher from $275.00 to $280.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 24th. UBS Group dropped their price target on shares of Danaher from $309.00 to $305.00 and set a “buy” rating on the stock in a research note on Wednesday. KeyCorp lifted their price target on shares of Danaher from $290.00 to $310.00 and gave the stock an “overweight” rating in a research note on Wednesday. Finally, Robert W. Baird dropped their price target on shares of Danaher from $278.00 to $277.00 and set an “outperform” rating on the stock in a research note on Wednesday. Seven research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to MarketBeat, Danaher currently has an average rating of “Moderate Buy” and a consensus target price of $287.28.

Danaher Stock Performance

Danaher stock opened at $245.41 on Friday. The company’s 50-day moving average price is $269.52 and its 200-day moving average price is $260.35. Danaher Co. has a twelve month low of $182.09 and a twelve month high of $281.70. The company has a quick ratio of 1.04, a current ratio of 1.43 and a debt-to-equity ratio of 0.33. The company has a market cap of $181.77 billion, a PE ratio of 41.59, a price-to-earnings-growth ratio of 4.49 and a beta of 0.83.

Danaher (NYSE:DHR) last posted its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, topping analysts’ consensus estimates of $1.57 by $0.14. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The firm had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.59 billion. During the same period in the previous year, the firm posted $2.02 EPS. The business’s quarterly revenue was up 3.1% on a year-over-year basis. On average, equities research analysts forecast that Danaher Co. will post 7.59 EPS for the current fiscal year.

Danaher Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, October 25th. Stockholders of record on Friday, September 27th were issued a $0.27 dividend. The ex-dividend date was Friday, September 27th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.44%. Danaher’s dividend payout ratio (DPR) is presently 18.31%.

Insider Transactions at Danaher

In related news, SVP Georgeann Couchara sold 952 shares of the company’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $268.37, for a total transaction of $255,488.24. Following the transaction, the senior vice president now directly owns 4,212 shares in the company, valued at approximately $1,130,374.44. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In related news, SVP Georgeann Couchara sold 952 shares of the company’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $268.37, for a total transaction of $255,488.24. Following the transaction, the senior vice president now directly owns 4,212 shares in the company, valued at approximately $1,130,374.44. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Matthew Mcgrew sold 16,172 shares of the company’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $279.84, for a total transaction of $4,525,572.48. Following the transaction, the chief financial officer now owns 29,407 shares in the company, valued at $8,229,254.88. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 30,059 shares of company stock worth $8,400,897 in the last three months. Insiders own 11.10% of the company’s stock.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.